TY - JOUR
T1 - Graded chronic noncancer pain distribution using the Graded Chronic Pain Scale-Revised framework
T2 - a cross-sectional study
AU - Hellmann, Sophie Sell
AU - Ekholm, Ola
AU - Handberg, Gitte
AU - Petersen, Pernille Lykke
AU - Kurita, Geana Paula
AU - Sjøgren, Per
AU - Thygesen, Lau Caspar
AU - Vaegter, Henrik Bjarke
N1 - Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.
PY - 2025/8
Y1 - 2025/8
N2 - INTRODUCTION: Chronic noncancer pain affects approximately one-fourth in population-based studies calling for more nuanced insights by applying the Graded Chronic Pain Scale-Revised (GCPS-R) framework for classifying graded chronic noncancer pain distribution in national disease surveillance. Objectives: The GCPS-R framework was included in the comprehensive questionnaire repeatedly used in the Danish National Health and Morbidity Surveillance program to provide more distinct measures for chronic non-malignant pain disease manifestation in Denmark.METHODS: A cross-sectional study inviting randomly 25,000 adults 16 years and older to self-report questionnaires comprising the GCPS-R framework as part of the nationwide Danish National Health Survey 2023. Prevalences (%) and multivariate-adjusted odds ratios (ORs) with 95% confidence intervals (95% CI) by ordinal logistic regression were calculated for GCPS-R by sex, area of living, age, country of origin, socioeconomic factors, body mass index, and Charlson Comorbidity Index.RESULTS: The prevalence of chronic noncancer pain was overall 28.1% (95% CI 27.2%-29.0%) in 8,643 included individuals without cancer diagnosis counting 7.4% (6.9%-8.0%) with mild-impact, 7.1% (6.6%-7.6%) with bothersome-impact, and 13.6% (12.9%-14.4%) with high-impact chronic noncancer pain. Women had 66% (odds ratio (OR) 1.66; 95% CI 1.50-1.84) elevated odds of more severely graded chronic noncancer pain referenced to men. Socioeconomic factors influenced odds inversely. Body mass index was related to GCPS-R by dose-response effects of more than doubled elevated odds in World Health Organization obese class II (2.42; 1.92-3.06) and obese class III (4.43; 3.30-5.93) referenced to normal body mass index individuals. Comorbidity elevated odds of more severely graded chronic noncancer pain by 86% (1.86; 1.57-2.19) referenced to individuals without comorbidity.CONCLUSIONS: More than one-quarter individuals reported chronic noncancer pain characterized particularly by high-impact graded chronic noncancer pain when applying the GCPS-R framework for classifying graded chronic noncancer pain distribution in national disease surveillance for rational health care administration.
AB - INTRODUCTION: Chronic noncancer pain affects approximately one-fourth in population-based studies calling for more nuanced insights by applying the Graded Chronic Pain Scale-Revised (GCPS-R) framework for classifying graded chronic noncancer pain distribution in national disease surveillance. Objectives: The GCPS-R framework was included in the comprehensive questionnaire repeatedly used in the Danish National Health and Morbidity Surveillance program to provide more distinct measures for chronic non-malignant pain disease manifestation in Denmark.METHODS: A cross-sectional study inviting randomly 25,000 adults 16 years and older to self-report questionnaires comprising the GCPS-R framework as part of the nationwide Danish National Health Survey 2023. Prevalences (%) and multivariate-adjusted odds ratios (ORs) with 95% confidence intervals (95% CI) by ordinal logistic regression were calculated for GCPS-R by sex, area of living, age, country of origin, socioeconomic factors, body mass index, and Charlson Comorbidity Index.RESULTS: The prevalence of chronic noncancer pain was overall 28.1% (95% CI 27.2%-29.0%) in 8,643 included individuals without cancer diagnosis counting 7.4% (6.9%-8.0%) with mild-impact, 7.1% (6.6%-7.6%) with bothersome-impact, and 13.6% (12.9%-14.4%) with high-impact chronic noncancer pain. Women had 66% (odds ratio (OR) 1.66; 95% CI 1.50-1.84) elevated odds of more severely graded chronic noncancer pain referenced to men. Socioeconomic factors influenced odds inversely. Body mass index was related to GCPS-R by dose-response effects of more than doubled elevated odds in World Health Organization obese class II (2.42; 1.92-3.06) and obese class III (4.43; 3.30-5.93) referenced to normal body mass index individuals. Comorbidity elevated odds of more severely graded chronic noncancer pain by 86% (1.86; 1.57-2.19) referenced to individuals without comorbidity.CONCLUSIONS: More than one-quarter individuals reported chronic noncancer pain characterized particularly by high-impact graded chronic noncancer pain when applying the GCPS-R framework for classifying graded chronic noncancer pain distribution in national disease surveillance for rational health care administration.
UR - http://www.scopus.com/inward/record.url?scp=105006694146&partnerID=8YFLogxK
U2 - 10.1097/PR9.0000000000001277
DO - 10.1097/PR9.0000000000001277
M3 - Journal article
C2 - 40444026
SN - 2471-2531
VL - 10
SP - e1277
JO - Pain Reports
JF - Pain Reports
IS - 4
ER -